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Introduction
Damage to DNA happens on a regular basis due to normal metab-
olism mishaps and external triggers. DNA breaks are categorized 
into two types: double strand and single strand. The healthy body 
has DNA repair pathways in place to repair both kinds of breaks. 
Both the Homologous Repair pathway and the Non-homologous 
End Joining repair pathway work to repair double strand breaks. 
The Base Excision repair pathway repairs single strand breaks. As 
long as there is damaged DNA in a cell, the cycle should be stopped, 
preventing the cell from dividing. If the damage cannot be repaired, 
the cell has systems in place to initiate apoptosis.  This paper ex-
plores the possibility of taking advantage of the systems in place to 
initiate apoptosis as a method of killing out tumorous cells.
Methods
The Touro database and PubMed.gov were used to find articles 
and original research regarding PARP inhibition in genetic cancers 
as well as cancers resulting from Homologous Recombination de-
ficiencies. Articles referenced in the articles found on the above 
mentioned databases were used as well.
Double Strand Break Repair Pathways
Although both the Homologous Recombination (HR) and Non-
homologous End Joining (NHEJ) repair pathways work to repair 
double strand breaks, the HR repair pathway is a much more 
reliable pathway. The HR pathway uses a sister chromatid as a 
template to repair the damage, which allows the repair to be ex-
tremely precise. Because sister chromatids are only available in 
the S and G2 phases of the cell cycle, HR occurs at those points 
in the cycle. NHEJ is a less complex process which does not re-
quire a template; the two broken ends are joined by ligation, a less 
precise process which often results in insertion or deletion of 
nucleotides (Murphy, 2010). (Figure 1)
The BRCA Gene: A Tumor Suppressor
The BRCA gene functions as a tumor suppressor gene, a catego-
ry of genes which repress the cell cycle and promote apoptosis. 
Tumor suppressor genes are in place to prevent damaged DNA 
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Figure1
Homologous recombination repair: A DNA lesion is recognized by the 
MRN (MRE11–RAD50–NBS1) complex, which is recruited to the DSB to 
generate single-stranded DNA by resection (see the figure; right panel). The 
single-stranded ends are bound by replication protein A (RPA), RAD51 and 
RAD52 and can subsequently invade the homologous template, creating 
a D-loop and a Holliday junction, to prime DNA synthesis and to copy and 
ultimately restore genetic information that was disrupted by the DSB.
HR: Homologous Recombination, NHEJ: Non-homologous End Joining
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from replicating and integrating into the genome.  The most estab-
lished role of the BRCA gene is its regulation of the Homologous 
Repair pathway. Cells with mutations in the BRCA gene thus lead 
the cell along the more error prone NHEJ pathway, causing an 
accumulation of chromosomal abnormalities and instability, which 
contributes to tumorigenesis. Mutations in the BRCA gene have 
been shown to cause a significant increase in the probability of 
developing tumors of the breast and ovaries. Breast cancer re-
sulting from a BRCA mutation, however, is unique in the sense 
that only the tumor cells are deficient in the HR repair pathway. 
Healthy cells have fully responsive repair pathways. This allows 
treatment targeting this deficiency to be specific only to tumor 
cells  (Murphy, 2010).
The Role of the PARP Enzyme in Single  
Strand Repair
The PARP enzymes’ main function is to initiate the Base Excision 
Repair pathway by recruiting specific proteins to the site of single 
strand DNA breaks; once the proteins are recruited, the PARPs 
are released and the resultant protein complex does the actual 
repair work. After initially binding to the DNA using its zinc fin-
ger domains, the PARP begins to transfer ADP ribose units from 
NAD+ to a variety of acceptor proteins, thus creating a negative 
charge which recruits the enzymes necessary for base excision 
repair (Drew, Calvert, 2008).  PARP inhibitors work either by trap-
ping the PARP on the DNA, preventing the protein complex from 
beginning its repair work, or by actually inhibiting the enzymatic 
activity.  Without PARP to initiate the Base Excision Repair pro-
cess, the single strand breaks accumulate and eventually develop 
into double strand breaks. (Figure 2)
Inhibition of the PARP Enzyme in BRCA 
Deficient cells is Synthetically Lethal
Inhibition of PARP causes an increase in DNA single strand breaks, 
which eventually evolve into double strand breaks at the site of 
the original damage. Cells with a functional BRCA network can 
respond to the inhibition of PARP through the use of the double 
strand repair pathways. Cells with deficient BRCA genes, however, 
are unable to properly respond to inhibition of PARP, leaving the 
double strand breaks without a reliable repair method, causing 
the two deficiencies to become a synthetically lethal combination 
(Warrener, et al., 2012).  Synthetic lethality is a condition by which 
deletion or inactivation of only one of two genes would not cause 
cell death, but deletion or inactivation of both of them is lethal 
(Reinbolt, 2013).  Thus, the inhibition of PARP in healthy cells is not 
necessarily lethal because the double strand break repair pathways 
can kick in to repair the damage. When paired with homologous 
repair deficiencies, however, the inhibition of PARP has proven to 
Figure 2: 
PARP: Poly-ADP Ribose Polymerase                   (intechopen.com)
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be lethal, because there are no efficient repair pathways for single 
or double strand damage. With no repair pathways in place, the 
cell is unable to maintain a stable cell cycle and should eventu-
ally undergo apoptosis. Inhibition of the PARP enzyme in tumor 
cells resulting from homologous repair deficiencies inhibits single 
strand repair mechanisms, initiating a selectively lethal response 
in the tumor cells, allowing for effective and targeted treatment.
Proteins Involved in the HR Pathway
Homologous recombination is a pathway which involves many dif-
ferent proteins. Identifying the roles these proteins play is a pos-
sible way of determining a biomarker to predict if tumor cells will 
respond to PARP inhibition. RAD51 is a protein which has been 
found to co-localize with BRCA2, which is suggestive of the inter-
connected roles they each play in homologous recombination. The 
HR pathway is initiated in either the S or G2 phases of the cell 
cycle by a double strand break. The broken ends then need to be 
resected to expose 3’ single stranded DNA tails, which need to 
be loaded with RAD51 in order to invade the identical homolo-
gous strand of the sister chromatid and form new identical DNA 
(Golmard, et al., 2013). BRCA2 has been shown to have binding 
sites for both DNA and RAD51 and thus facilitates the localiza-
tion and binding of RAD51 to the single strand DNA. Without 
the aid of BRCA2, the RAD51 is unable to bind to the DNA and 
the HR repair is unable to proceed (Murphy, 2010). BRCA1 is also 
involved in initiating double strand repair by playing an active role 
in resecting the broken DNA.
Cyclin-dependent kinases serve as regulators of the HR pathway 
through their roles in phosphorylation. They can phosphorylate 
BRCA2 at the RAD51 binding domain and thereby block the bind-
ing of DNA and RAD51. This decreases the rate of HR, and is 
meant to occur when the cell is exiting the G2 phase of the cycle, 
and HR can no longer occur. They also phosphorylate the protein 
CtIP, causing it to bind to a BRCA1 domain, which then becomes 
activated and is responsible for the resection of the broken strand 
of DNA to expose a 3’ tail, initiating the entire HR pathway.  Cells 
Figure 3:
HR: Homologous Repair, BER: Base Excision Repair                    (intechopen.com)
Figure 4: 
             (Google Images)
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without CtIP have been shown to have defects in the HR pathway, 
which is indicative of the involved role it plays in Homologous 
Recombination (Murphy, 2010).
ATM is a kinase involved in phosphorylating many proteins in-
volved in DNA repair and cell cycle check points. Cell cycle 
checkpoints are in place to ensure that there is no damaged DNA 
before the cell moves into the next phase. (Dujka, et al., 2010) 
Studies have been done to determine if lack of ATM induces sen-
sitivity to PARP inhibition, due to the lack of yet another DNA 
repair mechanism. ATM was genetically repressed in breast cancer 
cells which were then treated with Olaparib, a PARP inhibitor. The 
results were compared with a control group of breast cancer cells 
with active ATM. The control group cells got stuck at the G2/M 
checkpoint, but only the ATM depleted cells actually initiated 
apoptosis (Mantani, et al., 2013). These results indicate that ATM 
deficiency is not necessary for response to PARP inhibition but it 
does enhance the overall response greatly.  Deactivating ATM in 
a cell is a possible way of increasing the response it will have to 
PARP inhibition.
P53 is a tumor suppressor protein which is activated in response 
to DNA damage. P53 is normally held inactive by the mdm2 com-
plex, which it is bound to. In response to DNA damage, p53 dis-
associates from mdm2, and binds to the damaged DNA (Clegg, 
et al., 2012). Once activated, p53 activates p21, which then inhib-
its CDK2, a complex important in transitioning in the cell cycle 
(Zhao, et al., 2012). The cell cycle is then stopped, giving time for 
the proper repair proteins to be recruited to repair the damage. If 
the damage is repaired, then p53 is deactivated and the cell cycle 
continues. If the damage cannot be repaired, p53 initiates apop-
tosis. It has been found that p53 is somewhat regulated by the 
BRCA gene, implying that a mutation in BRCA will cause a similar 
deficiency in p53 (Murphy, 2010). This correlation explains why 
BRCA mutated cells are prone to becoming tumorous; the tumor 
suppression system regulated by p53 is not fully responsive, and 
is unable to properly respond to the unrepaired DNA damage.
Proteins as a Biomarker to Determine 
Sensitivity to PARP Inhibition
Identifying if cells are deficient in proteins involved in HR, such as 
RAD51, CtIP, ATM,  CDK’s and P53 can be a method of determin-
ing if a tumorous cell will respond to PARP inhibition. In addition, 
inducing mutations in these proteins and other proteins involved 
in DNA repair can be a way to prompt sensitivity to PARP inhi-
bition, even in cells that are not necessarily deficient in BRCA 
(Reinbolt, 2013).
Discussions
Trial experiments have been done to study the most effective way 
to take advantage of the synthetically lethal relationship between 
PARP inhibition and BRCA gene mutations. Different inhibitors 
have been identified and tested in varying doses. Various side ef-
fects have been identified, and the timing of the therapy has been 
experimented with. It is questionable whether to use PARP inhibi-
tion as a single agent or as an enhancing agent to other treatment 
options.
PARP inhibition has been shown to enhance the effects of DNA 
damaging agents, such as ionizing radiation and chemotherapy 
.The principle driving the success of  radiation therapy, for exam-
ple, is that oxidizing free radicals are induced to produce single 
and double strand breaks, prompting the tumorous cells to ini-
tiate apoptosis. (Abolfath, 2013) The role PARP plays in repairing 
DNA damage is a potential resistance mechanism to the desired 
effect of the radiation. Thus inhibition of the PARP enzymes is not 
only allowing the radiation to produce the desired results, but it 
enhances the effects by creating even more breaks (Basu, et al., 
2012).
Zinc deficiency and arsenic as potential PARP 
inhibitors
The zinc finger domains on PARP are what allow it to bind to 
DNA, beginning the whole Base Excision Repair process. Without 
being bound to DNA, PARP is essentially useless. Thus a deficiency 
in zinc ultimately leads to PARP inhibition due to the resultant 
inability of the PARP to bind to DNA. Research has also shown 
that arsenic can bind to the zinc finger domain in place of zinc, 
which changes the zinc finger structure, also preventing it from 
binding to DNA and causing it to lose all functionality (Sun, et al., 
2014). Practically, zinc levels can play a dual role: they are a pos-
sible biomarker to determine cell sensitivity to PARP inhibition 
and depletion of the metal is a method of inducing the inhibition. 
Arsenic, as well, although via a different mechanism than the oth-
ers, is considered to be a PARP inhibitor.
Olaparib as a monotherapy in BRCA1/2 
mutation associated breast cancers
In a study done in 2008, Olaparib, a PARP inhibitor taken orally, 
was administered to a group of women all possessing mutations in 
BRCA1 or BRCA2 genes. Olaparib was taken as a monotherapy, 
but all the patients had been given at least one chemotherapy 
regimen earlier. The study had 2 cohorts, the first was 400 mg 
of Olaparib, which was established to be the maximum tolera-
ble dose, taken twice daily. The second was 100 mg of Olaparib, 
also taken twice daily. Both study schedules lasted for 168 days. 
In the first cohort, 41% of the patients achieved the objective re-
sponse, with 4% achieving a complete response and 37% achieving 
a partial response. Forty four percent still had stable disease and 
15% had progressive disease. The second cohort had only 22% 
who achieved the objective response, with no patients achieving a 
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complete response. Forty four percent still had stable disease and 
33% had progressive disease (Tutt, et al., 2010). The results of this 
trial show definite response of tumor cells to Olaparib. The higher 
dosage produced better results compared to the lower dosage, 
implying an enhanced response when the dosage is raised.
Olaparib in combination with Paclitaxel
Triple negative breast cancer, TNBC, is defined by lack of recep-
tors for estrogen, progesterone, and human epithelial growth 
factor, and responds to few treatment options. TNBC has been 
shown to share similarities with BRCA1 associated breast can-
cers, (Nowsheen, et al., 2012) and a study was done in TNBC pa-
tients to determine the effect of combining PARP inhibition with 
Paclitaxel, a chemotherapy agent which stabilizes microtubules. 
The combined effect should prevent them from breaking down 
during cell division, causing the cell cycle to be stopped and apop-
tosis to be initiated. Patients received 200 mg of Olaparib twice 
daily and 90 mg of paclitaxel once a week for 6-10 28 day cycles. 
There was a greater than expected occurrence of neutropenia, 
a decrease in neutrophils which are responsible for destroying 
bacteria, within the first two cycles, a side effect also found in 
other studies done testing the combination of PARP inhibition 
with chemotherapy agents. Neutropenia is common side effect 
of Paclitaxel, but its occurrence increased significantly when com-
bined with PARP inhibition. At the point which patients were ex-
periencing neutropenia of grade 2 or higher, PARP inhibition was 
maintained, Paclitaxel administration was stopped and G-CSF was 
administered until the absolute neutrophil count (ANC) went up. 
If the absolute neutrophil count went up, Paclitaxel was contin-
ued, if it did not paclitaxel was discontinued. Although the rate 
of neutropenia occurrence increased, up to 40% of patients in 
the study showed partial response to the combined treatment, 
a greater response than has been seen with either treatment on 
its own (Dent, et al., 2013). Research is being done to understand 
the molecular reasoning of the increased neutropenia occurrence. 
Studies are also determining the best treatment schedule to min-
imize the side effects and maximize results.
Niraparib as a monotherapy in BRCA 
mutation carriers and sporadic cancers
Niraparib is also an oral PARP inhibitor and it has been studied as a 
monotherapy not only in carriers of the BRCA mutation carriers, 
but in patients with sporadic high grade serous ovarian cancer as 
well, which has a high prevalence of Homologous Recombination 
dysfunction. The study experimented with escalating doses to 
determine the maximum tolerable dose, which was found to be 
300 mg, taken twice daily. Thrombocytopenia and neutropenia 
presented as side effects but were easily controlled with dose 
reductions. Results of this study showed that greater response 
was seen in cells sensitive to platinum, a common base in chemo-
therapy agents, as opposed to platinum resistant cells. There was 
some response seen in platinum resistant cells, however, implying 
that the resistance mechanisms for PARP inhibition and platinum 
do not entirely overlap (Sandhu, et al., 2013).
The results of the above studies demonstrate the existence of a 
relationship between DNA damaging agents, such as chemothera-
py, and PARP inhibition. They also establish that PARP inhibition is 
not only effective in genetic tumors, but in other cancers involving 
homologous repair deficiencies. The relationship between PARP 
inhibition and platinum is logical, as they share a common goal of 
inducing DNA damage. The mechanisms of action, however, are 
clearly not the same because even the platinum resistant cells 
showed a response to PARP inhibition. Further understanding of 
the differences between the two and their resistance mechanisms 
must be understood in order to maximize the positive effect PARP 
inhibition can have on platinum resistant tumors. The response 
shown by the sporadic tumor cells shows promise in expanding 
PARP inhibition to include not only genetic cancers, but other 
cancers resulting from HR deficiencies. The key will be in finding a 
biomarker to determine which cells will respond positively.
Interferon Gamma as an enhancer of PARP 
inhibition
Because of the role they play in tumor suppression and cell cycle 
regulation, a study was done to determine if the interferon path-
way is affected by or involved in the synthetically lethal combina-
tion of PARP inhibition and BRCA gene mutations. The interferon 
pathway is a crucial response of the immune system to viruses, 
bacteria, and tumor cells. Interferons are proteins which have 
various functions, including regulation of the cell cycle, anti-viral 
responses, and apoptosis. Studies have suggested that interferons 
serve as regulators of the P53 gene, which is involved in the ini-
tiation of apoptosis (Takaoka, et al., 2003). H2AX is a gene which 
codes for the histone H2A, around which DNA gets wrapped, 
allowing for organized nucleosome formation. ATM is involved in 
the phosphorylation of H2A as a reaction to DNA double strand 
breaks in order to create space for the recruitment of repair pro-
teins.  Some of the interferons involved in cell cycle regulation and 
apoptosis are activated via an ATM dependent pathway, suggesting 
that an interconnected relationship exists between ATM, H2A, in-
terferons, P53, and PARP (Warrener, et al., 2012).
The above-mentioned study took BRCA silenced cells and stud-
ied the effect of PARP inhibition on interferon pathway activation. 
The PARP inhibited cells showed a three-fold increase in H2A 
phosphorylation, which is indicative of the increase in double 
strand breaks which results from the unrepaired single strand 
breaks. Enhanced activation of the interferon pathway was shown 
to correspond with the level of response to PARP inhibition, sug-
gesting that the role the pathway plays in promoting apoptosis 
serves as an enhancer to the effects of PARP inhibition. The study 
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also determined that when interferon gamma was administered 
together with the PARP inhibitors, the lethal response increased 
ten-fold, verifying the involvement of the interferon pathway 
in initiating apoptosis in PARP inhibited BRCA deficient cells 
(Warrener, et al., 2012).
Because of the role it plays in initiating double strand break repair, 
ATM depletion is another possible enhancer of PARP inhibition. 
When ATM is not active, H2A cannot be phosphorylated, which 
slows the response of the double strand break repair proteins. 
A decreased double strand repair response leads to more unre-
paired double strand breaks with no method of repairing them-
selves, thus increasing the amount of cells with sensitivity to PARP 
inhibition. This relationship was proven in a study which showed 
increased activation of the interferon pathway in ATM deficient 
cells, confirming both the dependency of successful PARP inhibi-
tion on lack of proper double strand repair mechanisms and the 
involvement of the interferon pathway in the apoptosis of PARP 
inhibited BRCA deficient cells (Warrener, et al., 2012).
Possible Resistance Mechanisms to  
PARP Inhibition
BRCA2 mutated cells have been found to develop resistance to 
platinum based chemotherapy due to the development of a sec-
ondary mutation which corrects the original mutation, restoring 
BRCA function (Wiedemeyer, et al., 2014). Cells harboring this 
resistance will also display resistance to PARP inhibition, whose 
success is dependent on a defective Homologous Recombination 
deficiency.  Not all platinum resistant tumor cells, however, devel-
op as a result of the secondary mutation; those cells are still ex-
pected to retain sensitivity to PARP inhibition (Weil, Chen, 2011).
P-gp, P-glycoprotein, is a protein of the cell membrane coded for 
by the ABCB1 gene that acts as a pump, pumping out foreign sub-
stances. This protein is involved in developing drug resistance, and 
has been shown to be the cause of resistance to some anti-can-
cer drugs. Up-regulation of the ABCB1 gene has been proven to 
demonstrate resistance to PARP inhibition due to the increased 
presence of P-gp. This resistance, however, has been counteracted 
with the administration of Tariquidar, a P-glycoprotein inhibitor 
(Weil, Chen, 2011).
53BP1 is a protein attached to DNA which is replaced by BRCA1 
during DNA damage repair. If 53BP1 is not replaced by BRCA1, 
the HR pathway becomes inhibited. If 53BP1 is absent in a cell, 
even in the case of a BRCA mutation, HR is still able to proceed 
because there is no 53BP1 which needs to be displaced. Only 
when 53BP1 is present and there is a BRCA mutation is HR ac-
tually impaired. An absence of 53BP1, therefore, is a possible re-
sistance mechanism to PARP inhibition, through its restoration of 
the HR pathway (Weil, Chen, 2011).
PARP inhibition as a proactive  
treatment option
 Until recently, BRCA1/BRCA2 mutation carriers have been faced 
with the disheartening knowledge that they will most likely de-
velop breast or ovarian cancer and the only proven preventative 
measure to be taken was prophylactic surgery. The evolution of 
PARP inhibition as a treatment option also introduces the possi-
bility of using PARP inhibition as a chemo-preventative measure 
for BRCA carriers who did not yet develop cancer, a much less 
drastic measure than prophylactic surgery. There have not been 
any conclusive studies done regarding using PARP inhibition as a 
preventative treatment, but the same mechanism it uses to selec-
tively kill tumor cells has been proposed as a way of preventing 
them from developing in the first place. Tumor cells resulting from 
BRCA deficiencies are the result of genetic alterations and defec-
tive DNA repair. Pre-exposing a BRCA mutation carrier to PARP 
inhibitors is a proposed method of killing the genetically altered 
cells, preventing them from developing into full blown tumors. It 
has also been proposed to use PARP inhibition as a means of 
preventing relapse, but no conclusive studies have been done at 
this point to investigate the possibility of success in this approach. 
Eventualities which must be considered in using PARP inhibition 
as a long term treatment option are the side effects as well as the 
danger in maintaining a defective repair pathway long term, espe-
cially in already high risk patients (Vinayek, Ford, 2010).
Conclusions
PARP inhibition shows promise on many different levels. The 
main factors to bear in mind in the development of treatment 
options are the specific target of only tumorous cells and minimal 
side effects, both of which are realized in PARP inhibition. The 
success of PARP inhibition expanded from genetically inherited 
breast cancers to other cancers resulting from DNA damage 
repair defects was demonstrated in clinical trials, which expands 
the network of patients eligible for treatment, making it easier 
to maintain the funding of research. PARP inhibition has elicited 
positive responses both as a mono-therapy and as an enhancer 
of other DNA damaging agents, such as chemotherapy and radia-
tion. The proteins involved in Homologous Recombination show 
great promise in functioning as predictive biomarkers of sensitivity 
to PARP inhibition. Further understanding of the roles they play 
will enable mutations of those proteins to be a method of in-
ducing and/or enhancing sensitivity to PARP inhibition. The hope 
that PARP inhibition presents not only as a treatment option but 
also as a precautionary alternative to prophylactic surgery makes 




PARP Poly ADP-ribose polymerase
HR Homologous Recombination
NHEJ Non-homologous End Joining
BER Base Excision Repair
ATM Ataxia Telangiectasia Mutated
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